Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Yasuo Fujii"'
Publikováno v:
Nihon Kikai Gakkai ronbunshu, Vol 87, Iss 899, Pp 21-00026-21-00026 (2021)
It will take a long time to put autonomous driving into practical in city road. Because the reliability of the technology for collecting traffic environment information and making appropriate driving judgment plans is still insufficient. Therefore, t
Externí odkaz:
https://doaj.org/article/5fc15933b3794cba80ccbc8b8e9fe01a
Publikováno v:
Journal of Clinical Psychopharmacology. 43:228-232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c70c42184311fee6c316cb268fc755ff
https://doi.org/10.1097/jcp.0000000000001672
https://doi.org/10.1097/jcp.0000000000001672
Publikováno v:
Journal of Clinical Psychopharmacology. 42:81-86
Background Although long-acting injectable antipsychotics (LAI-APs) have been considered as a monotherapeutic option in the maintenance treatment of schizophrenia, it has been recently reported that the combination therapy of LAI-APs and oral antipsy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93f826c55fe6acb2c6eb054e8496de73
https://doi.org/10.1097/jcp.0000000000001487
https://doi.org/10.1097/jcp.0000000000001487
Purpose: Patients with schizophrenia have a higher mortality risk than the general population. However, no recent studies have investigated mortality in people with schizophrenia in Japan. Therefore, we conducted a retrospective study to evaluate exc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6058c7cfaf9f9c5e0a7a80723f168846
https://doi.org/10.21203/rs.3.rs-2185284/v1
https://doi.org/10.21203/rs.3.rs-2185284/v1
Publikováno v:
International Clinical Psychopharmacology. 36:188-192
No studies have compared clinical outcomes after discontinuation of clozapine between patients who responded to clozapine and those who did not. Therefore, we examined 1-year clinical outcomes after clozapine discontinuation in responders and nonresp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22731fb5f1808b18db6495a18e35c181
https://doi.org/10.1097/yic.0000000000000361
https://doi.org/10.1097/yic.0000000000000361
Publikováno v:
The Journal of Clinical Psychiatry. 83
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::578a62736427a076be78f85dbb3aaeb4
https://doi.org/10.4088/jcp.21m14304
https://doi.org/10.4088/jcp.21m14304
Publikováno v:
Schizophrenia Research. 231:42-46
Long-acting injectable antipsychotics (LAI-APs) remain underutilized. One reason is the concern that LAI-APs might cause serious adverse events such as neuroleptic malignant syndrome (NMS) and lead to prolonged symptoms compared with oral treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58f452da1661e0f793fa91710e64333
https://doi.org/10.1016/j.schres.2021.02.016
https://doi.org/10.1016/j.schres.2021.02.016
Autor:
Hiroyoshi Takeuchi, Kenichi Tanimoto, Yasuo Fujii, Nozomi Nakajima, Yoshiki Kishi, Fuminari Misawa, Nao Mizoe, Toru Yamashita, Ryuhei So, Kohei Kitagawa
Publikováno v:
International Clinical Psychopharmacology. 36:84-88
Only a few studies have investigated changes in the dose of long-acting injectable second-generation antipsychotics (LAI-SGAs) over the long term in the maintenance treatment of schizophrenia. In this retrospective cohort study, we examined longitudi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25772949baa4e73e2d7324668a669147
https://doi.org/10.1097/yic.0000000000000347
https://doi.org/10.1097/yic.0000000000000347
Publikováno v:
Journal of clinical psychopharmacology. 41(6)
Purpose/background Although high-dose olanzapine might be a treatment option in patients with treatment-resistant schizophrenia, it can be reduced to the standard dose after symptoms are stabilized. We examined the rate of olanzapine reduction from h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba05e48c3491163a3a9892453cc52ca6
https://pubmed.ncbi.nlm.nih.gov/34735100
https://pubmed.ncbi.nlm.nih.gov/34735100
Publikováno v:
Journal of Clinical Psychopharmacology. 37:664-668
Background Clozapine has been regarded as the gold standard for patients with treatment-resistant schizophrenia, but a recent network meta-analysis has questioned its relative superiority over other second-generation antipsychotics (SGAs) such as ola
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a866a93bc6dfb928bcfadd94582e45
https://doi.org/10.1097/jcp.0000000000000798
https://doi.org/10.1097/jcp.0000000000000798